|
Abbott and Takeda Pharmaceutical Company Limited concluded their TAP Pharmaceutical Products Inc. (TAP) joint venture on April 30, 2008. The closing of the agreement to evenly divide the value of the more than 30-year-old joint venture marks the
conclusion of one of the most successful joint ventures in the history of American business.
Under terms of the agreement, Abbott receives rights to the product Lupron, including the commercial organization supporting that franchise. Takeda receives the rights to the product Prevacid, all the remaining TAP commercial and support organizations, and the rights to TAP's pipeline.
|
 |
At TAP, we are passionate about assisting qualified patients to receive the medication they need. Click here to learn about our Patient Assistance Programs. |
 |
|
